Suppr超能文献

脑肿瘤中组织型纤溶酶原激活剂含量的生物学意义。

Biological significance of tissue plasminogen activator content in brain tumors.

作者信息

Sawaya R, Rämö O J, Shi M L, Mandybur G

机构信息

Department of Neurosurgery, MD Anderson Cancer Center, Houston, Texas.

出版信息

J Neurosurg. 1991 Mar;74(3):480-6. doi: 10.3171/jns.1991.74.3.0480.

Abstract

Fresh brain-tumor samples were obtained at operation and analyzed for their content of tissue type plasminogen activator (tPA) using an activity assay (gel chromatography zymogram) and an enzyme-linked immunospecific assay. The specimens were taken from 23 glioblastomas, 35 metastatic tumors, 42 meningiomas, 16 low-grade gliomas, and seven acoustic neurinomas; seven specimens were from normal brain. A strong correlation was found between the results of the two assays (r = 0.77, p less than 0.0001). There was a threefold difference in the tPA content of the benign tumors as compared to malignant tumors (p = 0.0006), the latter having less tPA. Histologically benign meningiomas contained higher tPA than malignant meningiomas (p = 0.01); however, the difference between low-grade gliomas and high-grade gliomas was less evident. Overall regression analysis data have shown an inverse relationship between the tissue content in tPA and the presence and degree of tumor necrosis and peritumoral brain edema (p = 0.004 and p = 0.0004, respectively). This finding was most consistent in the glioblastoma group where the correlation coefficient values were r = 0.53 and r = -0.55, respectively. There was no significant correlation between the tissue tPA content and the age and sex, steroid use, or plasma tPA of the patients or the duration of symptoms. In summary, this is the first demonstration of tPA in a large series of human brain tumors and in normal brain. The differences observed have clear biological significance and, although the source of tPA in tumor tissue is still unknown, a relative reduction in tPA in tumor tissue may play an integral role in the development of tissue necrosis and tissue edema. The lack of tPA in tumor necrosis was not due to tissue destruction and cell death since urokinase was readily detectable in that tissue.

摘要

新鲜脑肿瘤样本于手术时获取,并使用活性测定法(凝胶色谱酶谱法)和酶联免疫特异性测定法分析其组织型纤溶酶原激活剂(tPA)含量。样本取自23例胶质母细胞瘤、35例转移性肿瘤、42例脑膜瘤、16例低级别胶质瘤和7例听神经瘤;7个样本来自正常脑组织。两种测定结果之间存在强相关性(r = 0.77,p小于0.0001)。良性肿瘤的tPA含量与恶性肿瘤相比存在三倍差异(p = 0.0006),后者的tPA含量较少。组织学上良性的脑膜瘤比恶性脑膜瘤含有更高的tPA(p = 0.01);然而,低级别胶质瘤和高级别胶质瘤之间的差异不太明显。总体回归分析数据显示tPA的组织含量与肿瘤坏死及瘤周脑水肿的存在和程度呈负相关(分别为p = 0.004和p = 0.0004)。这一发现在胶质母细胞瘤组中最为一致,其中相关系数值分别为r = 0.53和r = -0.55。组织tPA含量与患者的年龄、性别、类固醇使用情况、血浆tPA或症状持续时间之间无显著相关性。总之,这是首次在大量人类脑肿瘤及正常脑组织中证实tPA的存在。观察到的差异具有明确的生物学意义,尽管肿瘤组织中tPA的来源仍不清楚,但肿瘤组织中tPA的相对减少可能在组织坏死和组织水肿的发展中起重要作用。肿瘤坏死中缺乏tPA并非由于组织破坏和细胞死亡,因为在该组织中很容易检测到尿激酶。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验